Ivan Borrello

21.8k total citations · 7 hit papers
148 papers, 13.0k citations indexed

About

Ivan Borrello is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Ivan Borrello has authored 148 papers receiving a total of 13.0k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 77 papers in Immunology and 75 papers in Oncology. Recurrent topics in Ivan Borrello's work include Multiple Myeloma Research and Treatments (46 papers), Immunotherapy and Immune Responses (44 papers) and Hematopoietic Stem Cell Transplantation (38 papers). Ivan Borrello is often cited by papers focused on Multiple Myeloma Research and Treatments (46 papers), Immunotherapy and Immune Responses (44 papers) and Hematopoietic Stem Cell Transplantation (38 papers). Ivan Borrello collaborates with scholars based in United States, Italy and Canada. Ivan Borrello's co-authors include Paolo Serafini, Kimberly Noonan, Vincenzo Bronte, Eduardo M. Sotomayor, Hyam I. Levitsky, Drew M. Pardoll, Alexander M. Lesokhin, Li Zhu, Stephen M. Ansell and Philippe Armand and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ivan Borrello

143 papers receiving 12.8k citations

Hit Papers

PD-1 Blockade with Nivolumab in Rela... 1998 2026 2007 2016 2014 2007 2006 2006 2005 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    2014 2.7k citations Ivan Borrello et al. profile →
  2. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
    2007 925 citations Ivan Borrello et al. profile →
  3. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
    2006 632 citations Paolo Serafini, Ivan Borrello et al. profile →
  4. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
    2006 615 citations Paolo Serafini, Kimberly Noonan et al. profile →
  5. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression
    2005 601 citations Paolo Serafini, Ivan Borrello et al. profile →
  6. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
    1998 571 citations Ivan Borrello et al. profile →
  7. Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
    2008 557 citations Paolo Serafini, Stephanie Mgebroff et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ivan Borrello United States 45 7.3k 7.3k 3.5k 3.3k 1.3k 148 13.0k
Qing Yi United States 54 3.6k 0.5× 4.9k 0.7× 1.8k 0.5× 3.8k 1.1× 910 0.7× 197 9.8k
Ralf C. Bargou Germany 55 6.4k 0.9× 3.2k 0.4× 2.3k 0.7× 4.7k 1.4× 1.9k 1.5× 178 11.7k
Veronika Sexl Austria 51 3.6k 0.5× 4.4k 0.6× 1.5k 0.4× 3.3k 1.0× 717 0.6× 183 9.5k
Karin Tarte France 50 2.8k 0.4× 3.5k 0.5× 1.3k 0.4× 2.6k 0.8× 1.3k 1.0× 177 8.4k
Eduardo M. Sotomayor United States 51 4.9k 0.7× 6.6k 0.9× 626 0.2× 3.9k 1.2× 1.1k 0.9× 198 11.1k
Ulrich Dührsen Germany 51 3.0k 0.4× 3.2k 0.4× 3.1k 0.9× 2.2k 0.7× 3.3k 2.5× 283 10.3k
Mariusz A. Wasik United States 55 4.9k 0.7× 3.4k 0.5× 1.1k 0.3× 3.2k 1.0× 3.0k 2.3× 187 10.4k
Carmelo Carlo‐Stella Italy 40 3.0k 0.4× 2.1k 0.3× 2.4k 0.7× 2.4k 0.7× 1.9k 1.5× 350 9.1k
William Matsui United States 54 5.3k 0.7× 1.7k 0.2× 2.5k 0.7× 6.1k 1.8× 825 0.6× 154 10.8k
David Avigan United States 42 2.9k 0.4× 3.7k 0.5× 2.6k 0.7× 3.0k 0.9× 329 0.3× 208 7.5k

Countries citing papers authored by Ivan Borrello

Since Specialization
Citations

This map shows the geographic impact of Ivan Borrello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Borrello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Borrello more than expected).

Fields of papers citing papers by Ivan Borrello

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Borrello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Borrello. The network helps show where Ivan Borrello may publish in the future.

Co-authorship network of co-authors of Ivan Borrello

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Borrello. A scholar is included among the top collaborators of Ivan Borrello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Borrello. Ivan Borrello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hosoya, Hitomi, Paula Rodríguez‐Otero, Surbhi Sidana, & Ivan Borrello. (2023). Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact. American Society of Clinical Oncology Educational Book. 43(43). e389860–e389860. 2 indexed citations
3.
Huff, Carol Ann, Anna Ferguson, Lakshmi Rudraraju, et al.. (2021). An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical Cancer Research. 27(24). 6696–6708. 12 indexed citations
4.
Webster, Jonathan, Tara M. Robinson, Amanda L. Blackford, et al.. (2021). A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia Research. 111. 106737–106737. 4 indexed citations
5.
Zahurak, Marianna, Maria Bettinotti, Syed Abbas Ali, et al.. (2021). Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 27(11). 909.e1–909.e6. 10 indexed citations
6.
Shah, Nina, David Avigan, Jesús G. Berdeja, et al.. (2020). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for ImmunoTherapy of Cancer. 8(2). e000734–e000734. 31 indexed citations
7.
DeZern, Amy E., Hany Elmariah, Marianna Zahurak, et al.. (2020). Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation. 26(11). 2075–2081. 22 indexed citations
8.
Imus, Philip, Amanda L. Blackford, Maria Bettinotti, et al.. (2019). Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(12). 2431–2437. 56 indexed citations
9.
Lutz, Eric R., Valentina Hoyos, Lakshmi Rudraraju, et al.. (2018). Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy. Blood. 132(Supplement 1). 3337–3337. 3 indexed citations
10.
Gocke, Christian B., Qiuju Wang, Asma Begum, et al.. (2016). IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal. Molecular Cancer Therapeutics. 15(11). 2733–2739. 7 indexed citations
11.
Wang, Qiuju, Toshihiko Tanno, Zeshaan A. Rasheed, et al.. (2014). Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma. Molecular Cancer Therapeutics. 13(7). 1873–1881. 22 indexed citations
12.
Weed, Donald T., Jennifer L. Vella, Isildinha M. Reis, et al.. (2014). Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 21(1). 39–48. 215 indexed citations
13.
Bedi, Atul, Xiaofei Chang, Kimberly Noonan, et al.. (2012). Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy. Molecular Cancer Therapeutics. 11(11). 2429–2439. 59 indexed citations
14.
Noonan, Kimberly, Lakshmi Rudraraju, Anna Ferguson, et al.. (2012). Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses. Clinical Cancer Research. 18(5). 1426–1434. 83 indexed citations
15.
Gladstone, Douglas E., Javier Bolaños‐Meade, Carol Ann Huff, et al.. (2011). High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia & lymphoma. 52(11). 2076–2081. 4 indexed citations
16.
Serafini, Paolo, Stephanie Mgebroff, Kimberly Noonan, & Ivan Borrello. (2008). Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells. Cancer Research. 68(13). 5439–5449. 557 indexed citations breakdown →
17.
Huff, Carol Ann, Qiuju Wang, Javier Bolaños‐Meade, et al.. (2008). Correlation of clonogenic cancer stem cell (CSC) growth with clinical outcomes in multiple myeloma (MM) patients undergoing treatment with high dose cyclophosphamide (Cy) and rituximab. Cancer Research. 68. 5 indexed citations
18.
Borrello, Ivan, et al.. (1989). Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock.. PubMed. 4(1). 13–8. 39 indexed citations
19.
Fiore, Pier Paolo Di, Joseph Falco, Ivan Borrello, Bernard E. Weissman, & Stuart A. Aaronson. (1988). The Calcium Signal for BALB/MK Keratinocyte Terminal Differentiation Counteracts Epidermal Growth Factor (EGF) Very Early in the EGF-Induced Proliferative Pathway. Molecular and Cellular Biology. 8(2). 557–563. 8 indexed citations
20.
King, C. Richter, Ivan Borrello, F. Bellot, Paolo M. Comoglio, & Joseph Schlessinger. (1988). Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3.. The EMBO Journal. 7(6). 1647–1651. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qing Yi Breakdown of academic impact, for papers by Ralf C. Bargou Breakdown of academic impact, for papers by Veronika Sexl Breakdown of academic impact, for papers by Karin Tarte Breakdown of academic impact, for papers by Eduardo M. Sotomayor Breakdown of academic impact, for papers by Ulrich Dührsen Breakdown of academic impact, for papers by Mariusz A. Wasik Breakdown of academic impact, for papers by Carmelo Carlo‐Stella Breakdown of academic impact, for papers by William Matsui Breakdown of academic impact, for papers by David Avigan
Rankless by CCL
2026